Slingshot members are tracking this event:

FDA Grants Priority Review to Merck’s (MRK) Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA (pembrolizumab) for New Indication in Microsatellite Instability-High Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 28, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Supplemental Biologics License Application, Keytruda, Pembrolizumab, New Indication In Microsatellite Instability-